C-erbB-2基因在人肺腺癌细胞表达与药物治疗关系的研究

The study on the relationship between expression of C-erbB-2 oncogene in non-small cell lung cancer and anticarcinogens treatment

目的 观察紫杉醇、阿霉素和α 干扰素对不同C erbB 2表达水平的人肺腺癌细胞系增殖能力的影响 ,探讨C erbB 2基因和抗癌药物敏感性的关系。方法 采用免疫组化方法检测C erbB 2基因在肺癌细胞株 (SPC A 1、LTEP α 2和A5 49)中的表达 ,观察紫杉醇、阿霉素及α 干扰素干预前后 3株肺腺癌细胞系中C erbB 2基因表达率的变化 ;采用四氮唑盐 (MTT)比色法检测抗癌药物对人肺腺癌细胞体外增殖能力的影响 ,计算相应IC50 值 ;应用集落形成试验检测药物对肺腺癌细胞集落形成能力的影响 ;结合流式细胞术定量分析药物干预前后各细胞系DNA含量的变化。结果 SPC A 1、LTEP α 2和A5 493株肺腺癌细胞系均有不同水平C erbB 2基因的表达。紫杉醇对低表达C erbB 2基因的SPC A 1肺腺癌细胞系的抗增殖作用明显强于高表达C erbB 2基因的A5 49和LTEP α 2肺腺癌细胞系 ,阿霉素对具有不同C erbB 2表达水平的 3株人肺腺癌细胞系均较敏感 ,α 干扰素对 3株肺腺癌细胞均有一定的抑制作用 ,但较弱。在SPC A 1细胞株应用阿霉素和紫杉醇后、LTEP α 2细胞株应用阿霉素后 ,其C erbB 2基因的表达率明显减低 ,但A5 49肺腺癌细胞系C erbB 2表达率的变化无统计学差异。阿霉素和紫杉醇治疗后SPC A 1和LTEP α 2肺腺癌细胞系的G2 M期百分?

Objective To explore the effect of paclitaxel, doxorubicin and interferon-2联-on the multiplication capacity of human lung adenocarcinoma cell strain with different expression of C-erbB-2 and the relationship between the expression of C-erbB-2 and the sensitivity of anticancer medicines. Methods SABC immunohistochemical method was applied to detect C-erbB-2 oncogene expression in SPC-A-1, LTEP-α-2 and A549 cell lines. The cytotoxity of lung adenocarcinoma in vitro was examined by MTT method. The mitogenic capacity was detected by colony-forming assay. The cell cycle status was determined by flow cytometry. Results There were expressions of C-erbB-2 of different level in the three cell lines. The effect of doxorubicin on the three cell lines was higher than that of paclitaxel and doxorubicin. The effect of paclitaxel in SPC-A-1 cell line was significantly higher than that of A459 and LTEP-α-2 cell lines. The restrain action of IFN-α on the three cell lines was less. The expression of C-erbB-2 was markedly decreased in SPC-A-1 cell line treated with paclitaxel or doxorubicin and in LTEP-α-2 cell line treated with doxorubicin. The changes in the others were no significance. The percentages of G 2-M phase in SPC-A-1 and LTEP-α-2 cell lines treated with paclitaxel or doxorubicin were significantly increased. In contrast,the percentage of S phase in A549 was increased. The IFN-α had no noted effects on cell cycle status among the three cell lines.Conclusions The expression of C-erbB-2 may reduce the sensitivity of tumor cells to anticancer drugs. The detection of C-erbB-2 may be helpful to select therapy project for patients with NSCLC.